GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Altman Z-Score

The Oncology Institute (The Oncology Institute) Altman Z-Score : 0.16 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 0.16 is in distress zone. This implies bankruptcy possibility in the next two years.

The Oncology Institute has a Altman Z-Score of 0.16, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for The Oncology Institute's Altman Z-Score or its related term are showing as below:

TOI' s Altman Z-Score Range Over the Past 10 Years
Min: 0.16   Med: 1.18   Max: 5.7
Current: 0.16

During the past 6 years, The Oncology Institute's highest Altman Z-Score was 5.70. The lowest was 0.16. And the median was 1.18.


The Oncology Institute Altman Z-Score Historical Data

The historical data trend for The Oncology Institute's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute Altman Z-Score Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial - - 5.43 1.66 0.57

The Oncology Institute Quarterly Data
Sep18 Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.38 0.69 0.57 0.45

Competitive Comparison of The Oncology Institute's Altman Z-Score

For the Medical Care Facilities subindustry, The Oncology Institute's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute's Altman Z-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Altman Z-Score falls into.



The Oncology Institute Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The Oncology Institute's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.4665+1.4*-0.8118+3.3*-0.3272+0.6*0.2394+1.0*1.6756
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $204.5 Mil.
Total Current Assets was $141.2 Mil.
Total Current Liabilities was $45.8 Mil.
Retained Earnings was $-166.0 Mil.
Pre-Tax Income was -19.889 + -19.068 + -17.284 + -16.798 = $-73.0 Mil.
Interest Expense was -1.985 + 1.24 + -2.695 + -2.672 = $-6.1 Mil.
Revenue was 94.666 + 85.788 + 82.035 + 80.224 = $342.7 Mil.
Market Cap (Today) was $39.1 Mil.
Total Liabilities was $163.2 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(141.192 - 45.768)/204.532
=0.4665

X2=Retained Earnings/Total Assets
=-166.039/204.532
=-0.8118

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-73.039 - -6.112)/204.532
=-0.3272

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=39.080/163.236
=0.2394

X5=Revenue/Total Assets
=342.713/204.532
=1.6756

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

The Oncology Institute has a Altman Z-Score of 0.16 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


The Oncology Institute  (NAS:TOI) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


The Oncology Institute Altman Z-Score Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Oncology Institute (The Oncology Institute) Business Description

Traded in Other Exchanges
N/A
Address
18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Executives
Havencrest Healthcare Partners, L.p. 10 percent owner 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah officer: Chief Financial Officer, other: Principal Financial Officer C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively director, officer: Chief Executive Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle officer: Chief Operating Officer 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch director, officer: Executive Chairman C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos officer: Chief Medical Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit officer: Chief Accounting Officer, other: Principal Accounting Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal director 44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian 10 percent owner C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara director C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201